AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
AAPL   322.96 (-0.66%)
MSFT   183.33 (-1.17%)
FB   227.11 (-1.33%)
GOOGL   1,418.64 (-1.43%)
NVDA   351.81 (+0.29%)
BABA   219.25 (+0.11%)
MU   51.15 (+3.96%)
TSLA   878.72 (-0.48%)
AMD   52.51 (-0.42%)
T   31.51 (+0.00%)
F   6.35 (+2.58%)
DIS   123.10 (+0.75%)
BAC   26.32 (+1.27%)
BA   184.83 (+6.73%)
Log in

OTCMKTS:PXXLFPoxel Stock Price, Forecast & News

$8.99
0.00 (0.00 %)
(As of 06/4/2020 09:33 AM ET)
Add
Compare
Today's Range
$8.99
Now: $8.99
$8.99
50-Day Range
$6.18
MA: $6.47
$9.09
52-Week Range
$6.03
Now: $8.99
$15.35
Volume150 shs
Average Volume5,307 shs
Market Capitalization$216.57 million
P/E RatioN/A
Dividend YieldN/A
Beta1.23
Poxel SA, a biopharmaceutical company, develops drugs for metabolic diseases with a primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III clinical development stage that targets the organs of diabetes, such as pancreas, liver, and muscles. The company is also developing PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in Phase IIa clinical trial that controls body energy metabolism and treats chronic metabolic diseases, such as non-alcoholic steatohepatitis. Poxel SA has a licensing agreement with Enyo Pharmaceuticals for the development of PXL007 (EYP001), an FXR agonist that is in Phase I study for the treatment of Hepatitis B. The company was founded in 2009 and is headquartered in Lyon, France.
Read More
Poxel logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.48 out of 5 stars


Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:PXXLF
CUSIPN/A
CIKN/A
Phone33-4-37-37-20-10

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$88.11 million
Cash Flow$0.65 per share
Book Value$2.68 per share

Profitability

Miscellaneous

Employees33
Market Cap$216.57 million
Next Earnings DateN/A
OptionableNot Optionable

Receive PXXLF News and Ratings via Email

Sign-up to receive the latest news and ratings for PXXLF and its competitors with MarketBeat's FREE daily newsletter.

Poxel (OTCMKTS:PXXLF) Frequently Asked Questions

How has Poxel's stock been impacted by COVID-19 (Coronavirus)?

Poxel's stock was trading at $8.85 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PXXLF stock has increased by 1.6% and is now trading at $8.99. View which stocks have been most impacted by Coronavirus.

Has Poxel been receiving favorable news coverage?

Media stories about PXXLF stock have trended somewhat negative this week, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Poxel earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutPoxel.

Who are some of Poxel's key competitors?

Who are Poxel's key executives?

Poxel's management team includes the following people:
  • Mr. Thomas Kuhn Pharm D MBA, Co-Founder, CEO & Director
  • Mr. Sébastien Bolze Pharm D Ph.D., Co-Founder, Exec. VP of Non Clinical Devel. and Scientific Director
  • Ms. Pascale Fouqueray-Grellier, Co-Founder & Exec. VP of Early Devel. & Translational Medicine
  • Ms. Sophie Hallakou-Bozec, Co-Founder & Sr. VP of R&D Pharmacology
  • Ms. Anne Renevot, CFO & Director of Fin.s

What is Poxel's stock symbol?

Poxel trades on the OTCMKTS under the ticker symbol "PXXLF."

How do I buy shares of Poxel?

Shares of PXXLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Poxel's stock price today?

One share of PXXLF stock can currently be purchased for approximately $8.99.

How big of a company is Poxel?

Poxel has a market capitalization of $216.57 million and generates $88.11 million in revenue each year. Poxel employs 33 workers across the globe.

What is Poxel's official website?

The official website for Poxel is www.poxel.com.

How can I contact Poxel?

Poxel's mailing address is 259-261 Avenue Jean Jaures, Lyon I0, 69007. The company can be reached via phone at 33-4-37-37-20-10 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.